Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 25 studies | 47% ± 18% | |
astrocyte | 19 studies | 79% ± 15% | |
microglial cell | 16 studies | 56% ± 14% | |
oligodendrocyte | 15 studies | 71% ± 10% | |
fibroblast | 15 studies | 51% ± 16% | |
smooth muscle cell | 14 studies | 43% ± 17% | |
macrophage | 14 studies | 43% ± 17% | |
oligodendrocyte precursor cell | 14 studies | 75% ± 12% | |
glutamatergic neuron | 12 studies | 60% ± 21% | |
GABAergic neuron | 11 studies | 64% ± 22% | |
pericyte | 11 studies | 44% ± 14% | |
adipocyte | 10 studies | 64% ± 19% | |
mast cell | 9 studies | 42% ± 10% | |
mesothelial cell | 9 studies | 49% ± 17% | |
endothelial cell of lymphatic vessel | 9 studies | 42% ± 20% | |
epithelial cell | 8 studies | 45% ± 26% | |
T cell | 7 studies | 36% ± 16% | |
neuron | 7 studies | 48% ± 24% | |
plasma cell | 6 studies | 40% ± 21% | |
interneuron | 6 studies | 68% ± 20% | |
B cell | 6 studies | 41% ± 12% | |
ciliated cell | 6 studies | 55% ± 29% | |
Mueller cell | 6 studies | 62% ± 31% | |
myeloid cell | 6 studies | 43% ± 12% | |
monocyte | 6 studies | 38% ± 18% | |
cardiac muscle cell | 5 studies | 49% ± 9% | |
dendritic cell | 5 studies | 35% ± 7% | |
basal cell | 5 studies | 68% ± 23% | |
club cell | 5 studies | 53% ± 22% | |
type I pneumocyte | 5 studies | 60% ± 8% | |
type II pneumocyte | 5 studies | 57% ± 9% | |
cholangiocyte | 4 studies | 59% ± 14% | |
hepatocyte | 4 studies | 71% ± 23% | |
granule cell | 4 studies | 56% ± 18% | |
CD8-positive, alpha-beta T cell | 4 studies | 24% ± 8% | |
amacrine cell | 4 studies | 56% ± 5% | |
retina horizontal cell | 4 studies | 51% ± 10% | |
retinal cone cell | 4 studies | 61% ± 14% | |
retinal ganglion cell | 4 studies | 58% ± 15% | |
retinal rod cell | 4 studies | 49% ± 9% | |
natural killer cell | 4 studies | 37% ± 5% | |
hepatic stellate cell | 3 studies | 52% ± 17% | |
differentiation-committed oligodendrocyte precursor | 3 studies | 67% ± 13% | |
GABAergic interneuron | 3 studies | 64% ± 14% | |
glial cell | 3 studies | 57% ± 15% | |
progenitor cell | 3 studies | 43% ± 11% | |
CD4-positive, alpha-beta T cell | 3 studies | 28% ± 4% | |
vein endothelial cell | 3 studies | 34% ± 10% | |
GABAergic amacrine cell | 3 studies | 53% ± 9% | |
OFF-bipolar cell | 3 studies | 38% ± 7% | |
ON-bipolar cell | 3 studies | 40% ± 5% | |
glycinergic amacrine cell | 3 studies | 52% ± 8% | |
endothelial cell of vascular tree | 3 studies | 45% ± 2% | |
retinal pigment epithelial cell | 3 studies | 45% ± 21% | |
ependymal cell | 3 studies | 89% ± 1% | |
megakaryocyte-erythroid progenitor cell | 3 studies | 22% ± 8% | |
alveolar macrophage | 3 studies | 58% ± 6% | |
capillary endothelial cell | 3 studies | 38% ± 4% | |
myofibroblast cell | 3 studies | 44% ± 20% | |
respiratory goblet cell | 3 studies | 55% ± 22% | |
lymphocyte | 3 studies | 34% ± 11% | |
muscle cell | 3 studies | 37% ± 24% | |
leukocyte | 3 studies | 57% ± 16% | |
mucus secreting cell | 3 studies | 45% ± 14% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 1196.24 | 2642 / 2642 | 100% | 22.97 | 705 / 705 |
thymus | 100% | 1488.67 | 653 / 653 | 100% | 14.63 | 604 / 605 |
prostate | 100% | 665.18 | 245 / 245 | 100% | 12.08 | 500 / 502 |
kidney | 100% | 793.49 | 89 / 89 | 100% | 10.65 | 897 / 901 |
breast | 100% | 709.93 | 459 / 459 | 99% | 13.73 | 1112 / 1118 |
uterus | 100% | 765.92 | 170 / 170 | 98% | 8.58 | 452 / 459 |
adrenal gland | 100% | 543.74 | 258 / 258 | 98% | 9.26 | 226 / 230 |
ovary | 100% | 651.88 | 180 / 180 | 98% | 6.25 | 422 / 430 |
stomach | 100% | 407.89 | 358 / 359 | 98% | 7.10 | 280 / 286 |
lung | 99% | 479.25 | 573 / 578 | 98% | 7.18 | 1137 / 1155 |
skin | 99% | 522.18 | 1784 / 1809 | 99% | 8.49 | 466 / 472 |
pancreas | 98% | 315.59 | 321 / 328 | 99% | 6.98 | 177 / 178 |
intestine | 100% | 410.60 | 963 / 966 | 98% | 6.95 | 514 / 527 |
liver | 100% | 425.84 | 225 / 226 | 98% | 6.61 | 396 / 406 |
esophagus | 100% | 445.76 | 1441 / 1445 | 97% | 7.14 | 178 / 183 |
bladder | 100% | 625.05 | 21 / 21 | 95% | 6.82 | 477 / 504 |
adipose | 100% | 620.92 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 12.98 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 5.98 | 29 / 29 |
spleen | 100% | 382.74 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 8.91 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 4.52 | 1 / 1 |
blood vessel | 100% | 717.08 | 1333 / 1335 | 0% | 0 | 0 / 0 |
heart | 89% | 265.47 | 762 / 861 | 0% | 0 | 0 / 0 |
muscle | 63% | 120.26 | 502 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 52% | 164.92 | 481 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0097191 | Biological process | extrinsic apoptotic signaling pathway |
GO_0071560 | Biological process | cellular response to transforming growth factor beta stimulus |
GO_2001238 | Biological process | positive regulation of extrinsic apoptotic signaling pathway |
GO_0001649 | Biological process | osteoblast differentiation |
GO_0030178 | Biological process | negative regulation of Wnt signaling pathway |
GO_0072332 | Biological process | intrinsic apoptotic signaling pathway by p53 class mediator |
GO_0016055 | Biological process | Wnt signaling pathway |
GO_2001241 | Biological process | positive regulation of extrinsic apoptotic signaling pathway in absence of ligand |
GO_0048705 | Biological process | skeletal system morphogenesis |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005902 | Cellular component | microvillus |
GO_0005886 | Cellular component | plasma membrane |
GO_0005739 | Cellular component | mitochondrion |
GO_0005764 | Cellular component | lysosome |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0090575 | Cellular component | RNA polymerase II transcription regulator complex |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0019899 | Molecular function | enzyme binding |
GO_0016491 | Molecular function | oxidoreductase activity |
GO_0003713 | Molecular function | transcription coactivator activity |
GO_0005515 | Molecular function | protein binding |
Gene name | WWOX |
Protein name | WWOX isoform 4 WWOX isoform 5 WWOX isoform 3 WWOX isoform 7 WW domain-containing oxidoreductase WW domain containing oxidoreductase WW domain-containing oxidoreductase (EC 1.1.1.-) (Fragile site FRA16D oxidoreductase) (Short chain dehydrogenase/reductase family 41C member 1) WWOX isoform 8 |
Synonyms | WOX1 SDR41C1 FOR |
Description | FUNCTION: Putative oxidoreductase. Acts as a tumor suppressor and plays a role in apoptosis. Required for normal bone development (By similarity). May function synergistically with p53/TP53 to control genotoxic stress-induced cell death. Plays a role in TGFB1 signaling and TGFB1-mediated cell death. May also play a role in tumor necrosis factor (TNF)-mediated cell death. Inhibits Wnt signaling, probably by sequestering DVL2 in the cytoplasm. . |
Accessions | ENST00000569818.1 [Q9NZC7-4] ENST00000406884.6 [Q9NZC7-5] ENST00000355860.7 [Q9NZC7-3] A0A1Y0ZSQ6 ENST00000408984.7 [Q9NZC7-2] A0A411HBF4 A0A411HBG6 ENST00000683929.1 A0A1Y0ZJ50 A0A411HBH2 ENST00000627394.3 A0A411HBF5 A0A411HBD8 F5H3R5 A0A804HJX9 ENST00000539474.6 ENST00000566780.6 [Q9NZC7-1] A0A411HBG5 ENST00000402655.6 [Q9NZC7-6] Q9NZC7 A0A411HBC7 ENST00000569332.5 H3BMD1 A0A411HBG3 ENST00000566662.5 A0A0D9SER1 |